Dr. Reddy’s Laboratories Launches Its Generic Semaglutide Injection in Canada

Key Takeaways

• First generic semaglutide approved in Canada, a G7 first
• Dr. Reddy’s can price lower than brand Ozempic, expanding access
• Injection available in 2 mg and 4 mg prefilled pens
• Launch follows April 28 Health Canada NOC, enabling rapid entry
• Strengthens Dr. Reddy’s GLP‑1 portfolio ahead of global expansion

Pulse Analysis

The GLP‑1 class, led by Novo Nordisk’s Ozempic, has reshaped type‑2 diabetes care but its premium pricing limits patient uptake. By delivering a biosimilar-quality semaglutide at a generic price point, Dr. Reddy’s addresses a critical affordability gap, potentially unlocking broader adoption among Canadian patients who have struggled with cost barriers. Analysts anticipate that price competition could force the incumbent to adjust its Canadian pricing strategy, echoing trends seen in other markets where generics have entered the GLP‑1 space.

Canada’s regulatory milestone carries weight beyond its borders. As the first G7 country to grant market authorization for a generic semaglutide injection, Health Canada signals confidence in the drug’s manufacturing and clinical equivalence standards. This decision may accelerate similar approvals in the United States, Europe, and Japan, where health systems are also grappling with rising diabetes drug expenditures. The faster time‑to‑market—just days after the NOC—demonstrates Dr. Reddy’s robust supply chain and regulatory expertise, positioning the firm as a credible competitor in high‑complexity biologics.

Strategically, the launch bolsters Dr. Reddy’s broader GLP‑1 ambitions. Having already introduced the product in India under the Obeda® brand, the Canadian entry expands its geographic footprint and diversifies revenue streams. The move aligns with the company’s ESG narrative of improving patient access to essential medicines while pursuing sustainable growth. Looking ahead, Dr. Reddy’s is likely to target additional G7 markets, leveraging the Canadian approval as a reference point to negotiate pricing and reimbursement pathways worldwide.